ERBB2 and breast cancer: Despite the fact that PI3K/Akt signaling is a primary pathway for tumor development, in ER-negative/ERBB2-positive BC cells, ERBB2 has been shown to stimulate NF-kB through the canonical pathway independently of the PI3K axis.